Breaking News Instant updates and real-time market news.

TSRO

Tesaro

$145.90

-1.34 (-0.91%)

05:28
01/12/17
01/12
05:28
01/12/17
05:28

TESARO receives CRL from FDA for rolapitant IV NDA

TESARO announced that the FDA has issued a Complete Response Letter, or CRL, regarding the rolapitant IV New Drug Application, or NDA, for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. FDA requested additional information regarding the in vitro method utilized to demonstrate comparability of drug product produced at the two proposed commercial manufacturers for rolapitant IV that were included in the NDA. TESARO is working expeditiously to provide the requested information. The CRL did not identify concerns related to the safety or efficacy of rolapitant IV or request additional clinical studies. No concerns were raised regarding the active pharmaceutical ingredient, which is also used for the Varub oral product. TESARO identified potential deficiencies at the original contract manufacturer for rolapitant IV drug product, secured a second drug product supplier and included data from this manufacturer in the NDA. During the NDA review, FDA requested and TESARO provided in vitro data to demonstrate comparability of drug product made at the two manufacturing sites.

  • 30

    Jun

TSRO Tesaro
$145.90

-1.34 (-0.91%)

12/27/16
12/27/16
NO CHANGE
Target $151

Outperform
FBR Capital ups TESARO price target to $151
FBR Capital analyst Ed White raised his price target for TESARO to $151 from $133 and keeps the Outperform rating on the shares. The oncology-focused biopharmaceutical company closed Friday up $7.27 to $139.86. TESARO recently announced that the FDA has granted Priority Review for niraparib with a June 30, 2017 action date, White tells investors in a research note. He believes niraparib could be a potential blockbuster PARP inhibitor. Meanwhile, the launch of Varubi continues to "ramp up," with sequential quarter-over-quarter unit growth of 14%, the analyst writes. White says the drug achieved a 28% share of the oral NK-1 market in the U.S. in September.
01/04/17
GABE
01/04/17
NO CHANGE
GABE
Gabelli sees Incyte as more likely target following Gilead hire
Gilead (GILD) is more likely to buy Incyte (INCY) after naming Alessandro Riva to head its Hematology and Oncology Therapeutic unit, Gabelli analyst Jing He tells investors in a research note. Dr. Riva is a Novartis (NVS) veteran while Incyte is led by a team of Novartis veterans and has collaborated with Novartis Oncology on its key drug, Jakafi, the analyst points out. He believes Incyte is "big enough to move the needle" and bring long term growth to Gilead. The analyst lists Seattle Genetics (SGEN) and TESARO (TSRO) as other potential targets for the biotech giant. He believes Incyte is the "best fit."
01/09/17
LEER
01/09/17
NO CHANGE
Target $152
LEER
Outperform
TESARO price target raised to $152 from $115 at Leerink
Leerink analyst Seamus Fernandez raised his price target for TESARO to $152 from $115 to fully incorporate his high expectations for a broad label and reflect niraparib's transformation to a commercial stage asset. The analyst notes that the "strong data" from niraparib's NOVA trial, along with the lack of an expected FDA panel, should result in a broad label in the second-line or greater ovarian cancer maintenance setting, while ongoing niraparib trials in breast cancer and front-line ovarian cancer maintenance and the company's IO platform should be additional potential drivers of upside for the stock. Fernandez sees TESARO as an "attractive takeout target," and reiterates an Outperform rating on the shares.
01/10/17
LEER
01/10/17
NO CHANGE
LEER
Outperform
ARIAD acquisition supports potential takeout premium for TESARO, says Leerink
Leerink analyst Seamus Fernandez says the acquisition of ARIAD (ARIA) by Takeda (TKPYY) for $24 per share appears to be relatively in-line with other commercial stage acquisitions, and supports a potential acquisition price for TESARO (TSRO) of greater than $170 per share based on consensus forecasts. While TESARO remains well positioned to grow independently, the analyst believes a validated PARP inhibitor like niraparib could offer a durable and strategically important product opportunity for multiple suitors. He reiterates an Outperform rating on TESARO's shares.

TODAY'S FREE FLY STORIES

MS

Morgan Stanley

$55.84

0.49 (0.89%)

, AMZN

Amazon.com

$1,293.32

-1.68 (-0.13%)

16:25
01/18/18
01/18
16:25
01/18/18
16:25
General news
On The Fly: Top stock stories for Thursday »

Stocks opened little…

MS

Morgan Stanley

$55.84

0.49 (0.89%)

AMZN

Amazon.com

$1,293.32

-1.68 (-0.13%)

LGF.A

Lionsgate

$34.50

2.22 (6.88%)

LGF.B

Lionsgate

$32.84

2.46 (8.10%)

CBS

CBS

$60.00

1.1 (1.87%)

VIA

Viacom

$39.70

1.85 (4.89%)

VIAB

Viacom

$33.95

1.99 (6.23%)

BA

Boeing

$340.16

-10.85 (-3.09%)

ERJ

Embraer

$24.50

-0.19 (-0.77%)

GNC

GNC Holdings

$5.26

1.79 (51.59%)

PTC

PTC

$69.95

3.25 (4.87%)

AA

Alcoa

$53.00

-3.99 (-7.00%)

ENDP

Endo

$7.35

-0.34 (-4.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 19

    Jan

  • 31

    Jan

  • 01

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 15

    Feb

  • 21

    Feb

  • 18

    Mar

SRG

Seritage Growth Properties

$40.37

-0.4 (-0.98%)

16:25
01/18/18
01/18
16:25
01/18/18
16:25
Hot Stocks
Seritage Growth Properties sees FY17 leasing activity 2.6M sqf, up 26% on year »

Seritage Growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNST

Monster Beverage

$66.47

-0.6 (-0.89%)

16:25
01/18/18
01/18
16:25
01/18/18
16:25
Conference/Events
Monster Beverage to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

MGM

MGM Resorts

$36.07

-0.47 (-1.29%)

, WYNN

Wynn Resorts

$175.48

1.89 (1.09%)

16:23
01/18/18
01/18
16:23
01/18/18
16:23
Initiation
MGM Resorts, Wynn Resorts, Eldorado Resorts, Penn National initiated  »

MGM Resorts initiated…

MGM

MGM Resorts

$36.07

-0.47 (-1.29%)

WYNN

Wynn Resorts

$175.48

1.89 (1.09%)

ERI

Eldorado Resorts

$31.60

-0.4 (-1.25%)

PENN

Penn National

$32.26

-0.49 (-1.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BANF

BancFirst

$55.20

0.95 (1.75%)

16:22
01/18/18
01/18
16:22
01/18/18
16:22
Hot Stocks
BancFirst to raise company minimum wage »

Executive Chairman David…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTOR

Meritor

$23.82

-0.3 (-1.24%)

16:22
01/18/18
01/18
16:22
01/18/18
16:22
Hot Stocks
Meritor realigns segments and leadership positions »

Meritor is realigning its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 13

    Feb

  • 14

    Feb

BANF

BancFirst

$55.20

0.95 (1.75%)

16:21
01/18/18
01/18
16:21
01/18/18
16:21
Earnings
BancFirst reports Q4 EPS 59c, consensus 69c »

Due to the signing of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATHN

athenahealth

$125.53

-0.65 (-0.52%)

16:20
01/18/18
01/18
16:20
01/18/18
16:20
Initiation
athenahealth initiated  »

athenahealth initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

VIX

Volatility Index S&P 500 Options

16:20
01/18/18
01/18
16:20
01/18/18
16:20
Options
Closing CBOE SPX and VIX Index summary for January 18th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXP

American Express

$99.86

-0.9 (-0.89%)

16:19
01/18/18
01/18
16:19
01/18/18
16:19
Hot Stocks
Breaking Hot Stocks news story on American Express »

American Express down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

MRCY

Mercury Systems

$51.26

-0.45 (-0.87%)

16:19
01/18/18
01/18
16:19
01/18/18
16:19
Hot Stocks
Mercury Systems receives $12.5M electronic surveillance subsystem order »

Mercury Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

HCLP

Hi-Crush Partners

$12.00

-0.05 (-0.41%)

16:18
01/18/18
01/18
16:18
01/18/18
16:18
Hot Stocks
Hi-Crush Partners increases distribution to 20c per unit for Q4 »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FFBC

First Financial Bancorp

$27.75

-0.4 (-1.42%)

16:17
01/18/18
01/18
16:17
01/18/18
16:17
Earnings
First Financial Bancorp reports Q4 adjusted EPS 45c, consensus 40c »

Claude Davis, CEO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

$NSD

NASDAQ Market Internals

16:17
01/18/18
01/18
16:17
01/18/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCRI

Monarch Casino

$45.40

-0.5 (-1.09%)

16:16
01/18/18
01/18
16:16
01/18/18
16:16
Initiation
Monarch Casino initiated  »

Monarch Casino initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LVS

Las Vegas Sands

$73.73

0.22 (0.30%)

16:16
01/18/18
01/18
16:16
01/18/18
16:16
Initiation
Las Vegas Sands initiated  »

Las Vegas Sands initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

EPR

EPR Properties

$59.55

-1.24 (-2.04%)

16:16
01/18/18
01/18
16:16
01/18/18
16:16
Hot Stocks
EPR Properties raises monthly dividend to 36c from 34c »

The dividend of $0.36 per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPP

Green Plains Partners

$18.00

0.1 (0.56%)

16:16
01/18/18
01/18
16:16
01/18/18
16:16
Hot Stocks
Green Plains Partners increases quarterly distribution »

Green Plains Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FFBC

First Financial Bancorp

$27.75

-0.4 (-1.42%)

16:16
01/18/18
01/18
16:16
01/18/18
16:16
Earnings
First Financial Bancorp reports Q4 EPS 40c, consensus 40c »

Net interest margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

RNR

RenaissanceRe

$121.24

-1.68 (-1.37%)

, APO

Apollo Global

$35.07

-0.35 (-0.99%)

16:16
01/18/18
01/18
16:16
01/18/18
16:16
Hot Stocks
RenaissanceRe to acquire minority shareholding in Catalina »

Catalina Holdings Ltd and…

RNR

RenaissanceRe

$121.24

-1.68 (-1.37%)

APO

Apollo Global

$35.07

-0.35 (-0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 01

    Feb

GLPI

Gaming and Leisure Properties

$36.42

-0.34 (-0.92%)

16:16
01/18/18
01/18
16:16
01/18/18
16:16
Initiation
Gaming and Leisure Properties initiated  »

Gaming and Leisure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

16:16
01/18/18
01/18
16:16
01/18/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$175.48

1.89 (1.09%)

16:15
01/18/18
01/18
16:15
01/18/18
16:15
Initiation
Wynn Resorts initiated  »

Wynn Resorts initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INDB

Independent Bank

$72.45

-1.5 (-2.03%)

16:15
01/18/18
01/18
16:15
01/18/18
16:15
Earnings
Independent Bank reports Q4 EPS adjusted 89c, consensus 89c »

Total assets of $8.1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

PENN

Penn National

$32.26

-0.49 (-1.50%)

16:15
01/18/18
01/18
16:15
01/18/18
16:15
Initiation
Penn National initiated  »

Penn National initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.